董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Adam Elsesser | 男 | Chairman of the Board and Chief Executive Officer | 63 | 85.16万美元 | 121.44 | 2025-09-01 |
| Arani Bose | 男 | Director | 63 | 25.99万美元 | 31.43 | 2025-09-01 |
| Harpreet Grewal | 男 | Director | 58 | 26.74万美元 | 0.87 | 2025-09-01 |
| Bridget O'Rourke | 女 | Director | 57 | 28.99万美元 | 0.50 | 2025-09-01 |
| Thomas Wilder | 男 | Director | 61 | 28.81万美元 | 0.51 | 2025-09-01 |
| Janet Leeds | 女 | Director | 63 | 28.24万美元 | 0.55 | 2025-09-01 |
| Surbhi Sarna | 女 | Director | 39 | 27.49万美元 | 0.31 | 2025-09-01 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Adam Elsesser | 男 | Chairman of the Board and Chief Executive Officer | 63 | 85.16万美元 | 121.44 | 2025-09-01 |
| Johanna Roberts | 女 | Executive Vice President, General Counsel and Secretary | 53 | 242.79万美元 | 5.70 | 2025-09-01 |
| Lambert Shiu | 男 | Chief Accounting Officer | 45 | 217.96万美元 | 2.56 | 2025-09-01 |
| Maggie Yuen | 女 | Chief Financial Officer | 53 | 242.80万美元 | 1.38 | 2025-09-01 |
| Shruthi Narayan | 女 | President | 41 | 437.69万美元 | 未持股 | 2025-09-01 |
董事简历
中英对照 | 中文 | 英文- Adam Elsesser
-
Adam Elsesser联合创立了Penumbra并自公司于2004年成立起担任首席执行官和董事会成员，2015年1月成为公司的董事长和总裁。在Penumbra之前，Elsesser先生领导了SMART Therapeutics股份有限公司（SMART Therapeutics, Inc.，一家医疗设备公司，专注于神经介入治疗装置），担任首席执行官（2000-2002年），并且，后来被Boston Scientific 公司（Boston Scientific Corporation）收购，2002-2005年担任Boston Scientific 公司（Boston Scientific Corporation）的智能疗法的总裁。在他在医疗设备行业工作之前，Elsesser先生是律师事务所Shartsis Friese有限责任合伙公司（Shartsis Friese, LLP）的合伙人。他拥有斯坦福大学（Stanford University ）学士学位和黑斯廷斯法律学院（Hastings College of the Law）博士学位。
Adam Elsesser,co-founded Penumbra and has served as Chief Executive Officer and a member of the Board since inception in June 2004, as Chairman of the Board since January 2015, and as President from January 2015 until August 2019 and again from May 2020 until September 2025. Prior to Penumbra, Mr. Elsesser led SMART Therapeutics, Inc. (SMART Therapeutics), a medical device company focused on devices for neuro-intervention, as its Chief Executive Officer from 2000 to 2002 and, after its acquisition by Boston Scientific Corporation, as President of SMART Therapeutics within Boston Scientific Corporation from 2002 to 2005. Before his work in the medical device industry, Mr. Elsesser was a partner in the law firm of Shartsis Friese LLP. Mr. Elsesser received a B.A. from Stanford University and a J.D. from UC Law San Francisco, formerly Hastings College of the Law. - Adam Elsesser联合创立了Penumbra并自公司于2004年成立起担任首席执行官和董事会成员，2015年1月成为公司的董事长和总裁。在Penumbra之前，Elsesser先生领导了SMART Therapeutics股份有限公司（SMART Therapeutics, Inc.，一家医疗设备公司，专注于神经介入治疗装置），担任首席执行官（2000-2002年），并且，后来被Boston Scientific 公司（Boston Scientific Corporation）收购，2002-2005年担任Boston Scientific 公司（Boston Scientific Corporation）的智能疗法的总裁。在他在医疗设备行业工作之前，Elsesser先生是律师事务所Shartsis Friese有限责任合伙公司（Shartsis Friese, LLP）的合伙人。他拥有斯坦福大学（Stanford University ）学士学位和黑斯廷斯法律学院（Hastings College of the Law）博士学位。
- Adam Elsesser,co-founded Penumbra and has served as Chief Executive Officer and a member of the Board since inception in June 2004, as Chairman of the Board since January 2015, and as President from January 2015 until August 2019 and again from May 2020 until September 2025. Prior to Penumbra, Mr. Elsesser led SMART Therapeutics, Inc. (SMART Therapeutics), a medical device company focused on devices for neuro-intervention, as its Chief Executive Officer from 2000 to 2002 and, after its acquisition by Boston Scientific Corporation, as President of SMART Therapeutics within Boston Scientific Corporation from 2002 to 2005. Before his work in the medical device industry, Mr. Elsesser was a partner in the law firm of Shartsis Friese LLP. Mr. Elsesser received a B.A. from Stanford University and a J.D. from UC Law San Francisco, formerly Hastings College of the Law.
- Arani Bose
-
Arani Bose在2004年联合创立了Penumbra，并且在公司成立起担任公司的董事会成员。Bose博士是公司的董事长和医疗总监（2005-2015年），目前担任首席创新者。在创立Penumbra之前，Bose博士是纽约大学医学院（New York University NYU School of Medicine）放射科和神经科助理教授（1997-2004年），他也有一个临床实践。在NYU的时候，Bose博士联合创立了智能疗法。他拥有斯坦福大学（Stanford University）学士学位和科罗拉多大学医学院（University of Colorado School of Medicine）硕士学位，拥有耶鲁大学医学院（Yale University School of Medicine）和NYU医学中心（NYU Medical Center）住院医师实习和奖学金。
Arani Bose,co-founded Penumbra in June 2004 and has served as a member of the Board since inception. Dr. Bose was Chairman of the Board and Chief Medical Officer from 2005 until 2015 and served as Chief Innovator from 2015 until March 2022. Prior to founding Penumbra, Dr. Bose was an Assistant Professor of Radiology and Neurology at New York University (NYU) School of Medicine from 1997 to 2004, where he also had a clinical practice. While at NYU, Dr. Bose co-founded SMART Therapeutics. Dr. Bose received a B.A. from Stanford University and an M.D. from the University of Colorado School of Medicine with residency and fellowships at Yale University School of Medicine and NYU Medical Center. - Arani Bose在2004年联合创立了Penumbra，并且在公司成立起担任公司的董事会成员。Bose博士是公司的董事长和医疗总监（2005-2015年），目前担任首席创新者。在创立Penumbra之前，Bose博士是纽约大学医学院（New York University NYU School of Medicine）放射科和神经科助理教授（1997-2004年），他也有一个临床实践。在NYU的时候，Bose博士联合创立了智能疗法。他拥有斯坦福大学（Stanford University）学士学位和科罗拉多大学医学院（University of Colorado School of Medicine）硕士学位，拥有耶鲁大学医学院（Yale University School of Medicine）和NYU医学中心（NYU Medical Center）住院医师实习和奖学金。
- Arani Bose,co-founded Penumbra in June 2004 and has served as a member of the Board since inception. Dr. Bose was Chairman of the Board and Chief Medical Officer from 2005 until 2015 and served as Chief Innovator from 2015 until March 2022. Prior to founding Penumbra, Dr. Bose was an Assistant Professor of Radiology and Neurology at New York University (NYU) School of Medicine from 1997 to 2004, where he also had a clinical practice. While at NYU, Dr. Bose co-founded SMART Therapeutics. Dr. Bose received a B.A. from Stanford University and an M.D. from the University of Colorado School of Medicine with residency and fellowships at Yale University School of Medicine and NYU Medical Center.
- Harpreet Grewal
-
Harpreet Grewal自2015年1月起在公司的董事会工作。Wang先生是Orlucent股份有限公司（Orlucent, Inc.，一家早期诊断公司）的首席执行官（2012年起）。1999-现在，他通过Wang Ventures（一个家族式投资合伙制和其他相关股权公司）研究、建议和投资医疗设备、财务和技术创业公司。另外，Wang先生通过W5 Investments（一家房地产公司）投资、开发和管理房地产。他在1989年加入U-Jin Enterprises股份有限公司（U-Jin Enterprises, Inc.，一家食品处理和进口/出口公司）开始他的职业生涯。他拥有南加州大学（University of Southern California ）学士学位。
Harpreet Grewal,has served on the Board since April 2015. Mr. Grewal is the Founding Partner and CEO of 123G LLC. Through its operator work, 123G LLC works with high-growth companies to execute on defined business outcomes. Previously, Mr. Grewal served as Chief Operating Officer of Volante Technologies Inc., a global provider of software for the integration, processing and orchestration of payments and financial messages, from September 2019 until September 2023, where he also served on the Board of Directors from 2014 to 2020 and served as Executive in Residence from April 2018 to March 2019. From February 2016 through April 2017, Mr. Grewal served as General Manager of Constant Contact, Inc. (Constant Contact), a technology company primarily focused on marketing tools and a wholly-owned indirect subsidiary of Endurance International Group Holdings, Inc. (Endurance). Prior to the acquisition of Constant Contact by Endurance, from 2010 to February 2016, Mr. Grewal served as Executive Vice President and Chief Financial Officer of Constant Contact. In December 2019, Mr. Grewal settled litigation instituted by the SEC alleging that Mr. Grewal violated the antifraud provisions of Section 17(a) of the Securities Act of 1933, as amended (the Securities Act), Section 10(b) of the Exchange Act and Rule 10b-5 promulgated under the Exchange Act, and violated, or aided and abetted the violation of, the reporting, record-keeping and internal controls requirements of Section 13(a), Section 13(b)(2)(A) and related rules under the Exchange Act in connection with his position at Constant Contact. Without admitting or denying the SEC's allegations, Mr. Grewal consented to the entry of a Final Judgment that permanently enjoined him from future violations of Section 17(a) of the Securities Act and from aiding and abetting future violations of Section 13(a) or Section 13(b)(2)(A) of the Exchange Act, and required him to pay a fine of $350,000, including a $100,000 civil penalty. From 2008 to 2009, Mr. Grewal worked as an independent consultant to small businesses and early-stage entrepreneurs. From 2006 through 2008, Mr. Grewal was Executive Vice President and Chief Financial Officer of VistaPrint, Ltd. (VistaPrint), a publicly-traded online printing and marketing services company. Prior to VistaPrint, Mr. Grewal was Senior Vice President and Chief Financial Officer of GoldenSource Corporation, a data management company, from 2002 to 2006, Chief Financial Officer of eGain Communications Corporation, a customer engagement services company, from 1999 to 2002, and held various financial and strategic planning positions with PepsiCo, Inc., a publicly-traded food and beverage company, from 1996 to 1999. Mr. Grewal received a B.A. from the University of California, Berkeley and a M.A. from Johns Hopkins University. - Harpreet Grewal自2015年1月起在公司的董事会工作。Wang先生是Orlucent股份有限公司（Orlucent, Inc.，一家早期诊断公司）的首席执行官（2012年起）。1999-现在，他通过Wang Ventures（一个家族式投资合伙制和其他相关股权公司）研究、建议和投资医疗设备、财务和技术创业公司。另外，Wang先生通过W5 Investments（一家房地产公司）投资、开发和管理房地产。他在1989年加入U-Jin Enterprises股份有限公司（U-Jin Enterprises, Inc.，一家食品处理和进口/出口公司）开始他的职业生涯。他拥有南加州大学（University of Southern California ）学士学位。
- Harpreet Grewal,has served on the Board since April 2015. Mr. Grewal is the Founding Partner and CEO of 123G LLC. Through its operator work, 123G LLC works with high-growth companies to execute on defined business outcomes. Previously, Mr. Grewal served as Chief Operating Officer of Volante Technologies Inc., a global provider of software for the integration, processing and orchestration of payments and financial messages, from September 2019 until September 2023, where he also served on the Board of Directors from 2014 to 2020 and served as Executive in Residence from April 2018 to March 2019. From February 2016 through April 2017, Mr. Grewal served as General Manager of Constant Contact, Inc. (Constant Contact), a technology company primarily focused on marketing tools and a wholly-owned indirect subsidiary of Endurance International Group Holdings, Inc. (Endurance). Prior to the acquisition of Constant Contact by Endurance, from 2010 to February 2016, Mr. Grewal served as Executive Vice President and Chief Financial Officer of Constant Contact. In December 2019, Mr. Grewal settled litigation instituted by the SEC alleging that Mr. Grewal violated the antifraud provisions of Section 17(a) of the Securities Act of 1933, as amended (the Securities Act), Section 10(b) of the Exchange Act and Rule 10b-5 promulgated under the Exchange Act, and violated, or aided and abetted the violation of, the reporting, record-keeping and internal controls requirements of Section 13(a), Section 13(b)(2)(A) and related rules under the Exchange Act in connection with his position at Constant Contact. Without admitting or denying the SEC's allegations, Mr. Grewal consented to the entry of a Final Judgment that permanently enjoined him from future violations of Section 17(a) of the Securities Act and from aiding and abetting future violations of Section 13(a) or Section 13(b)(2)(A) of the Exchange Act, and required him to pay a fine of $350,000, including a $100,000 civil penalty. From 2008 to 2009, Mr. Grewal worked as an independent consultant to small businesses and early-stage entrepreneurs. From 2006 through 2008, Mr. Grewal was Executive Vice President and Chief Financial Officer of VistaPrint, Ltd. (VistaPrint), a publicly-traded online printing and marketing services company. Prior to VistaPrint, Mr. Grewal was Senior Vice President and Chief Financial Officer of GoldenSource Corporation, a data management company, from 2002 to 2006, Chief Financial Officer of eGain Communications Corporation, a customer engagement services company, from 1999 to 2002, and held various financial and strategic planning positions with PepsiCo, Inc., a publicly-traded food and beverage company, from 1996 to 1999. Mr. Grewal received a B.A. from the University of California, Berkeley and a M.A. from Johns Hopkins University.
- Bridget O'Rourke
-
Bridget O'Rourke，自2017年4月起担任董事会成员。二十多年来，奥罗克女士担任过多个行政和领导职务，在不同行业拥有专长。最近，O‘Rourke女士于2016年7月至2017年5月期间担任专为信用合作社行业提供服务的精品公司O’Rourke & Associates的猎头和咨询业务执行董事。2008年8月至2016年6月，奥罗克女士担任全球资产管理公司Passport Capital，LLC的人力资源主管。在加入Passport Capital，LLC之前，1997年至2007年，O‘Rourke女士曾在金融服务和猎头行业担任多个职位，包括担任O’Rourke Career Connections的猎头总监、多基金风险投资公司Sigma Partners的财务总监，以及花旗银行全球资产管理公司另类投资策略集团的副总裁。1991年7月至1996年12月，O'Rourke女士在Coopers & Lybrand（现称普华永道）担任审计和内部审计咨询职位，职责日益增加。奥罗克女士获得了加州大学圣巴巴拉分校的学士学位，并于1995年成为一名注册会计师。她担任董事会副主席，2011年至2020年担任旧金山消防信用合作社审计委员会主席。
Bridget O'Rourke,has served on the Board since April 2017. Ms. O'Rourke has held a number of executive and leadership positions over more than twenty years, with expertise across different industries. Most recently, Ms.O'Rourke served as Executive Director of the executive search and consulting practice of O'Rourke & Associates, a boutique firm providing services exclusively for the credit union industry, from July 2016 until May 2017. From August 2008 to June 2016, Ms.O'Rourke was Head of Human Resources at Passport Capital, LLC, a global asset management firm. Prior to Passport Capital, LLC, from 1997 to 2007 Ms.O'Rourke served in various positions in the financial services and executive search industries, including as Executive Search Director at O'Rourke Career Connections, Controller at Sigma Partners, a multi-fund venture capital firm, and Vice President for Citibank Global Asset Management's Alternative Investment Strategies group. From July 1991 to December 1996, Ms.O'Rourke held audit and internal audit consulting positions of increasing responsibility at Coopers & Lybrand (now known as PricewaterhouseCoopers). Ms.O'Rourke received a B.A. from the University of California, Santa Barbara and became a Certified Public Accountant in 1995. She served on the Board of Directors as Vice Chair and was Audit Committee Chair of the San Francisco Fire Credit Union from 2011 through 2020. - Bridget O'Rourke，自2017年4月起担任董事会成员。二十多年来，奥罗克女士担任过多个行政和领导职务，在不同行业拥有专长。最近，O‘Rourke女士于2016年7月至2017年5月期间担任专为信用合作社行业提供服务的精品公司O’Rourke & Associates的猎头和咨询业务执行董事。2008年8月至2016年6月，奥罗克女士担任全球资产管理公司Passport Capital，LLC的人力资源主管。在加入Passport Capital，LLC之前，1997年至2007年，O‘Rourke女士曾在金融服务和猎头行业担任多个职位，包括担任O’Rourke Career Connections的猎头总监、多基金风险投资公司Sigma Partners的财务总监，以及花旗银行全球资产管理公司另类投资策略集团的副总裁。1991年7月至1996年12月，O'Rourke女士在Coopers & Lybrand（现称普华永道）担任审计和内部审计咨询职位，职责日益增加。奥罗克女士获得了加州大学圣巴巴拉分校的学士学位，并于1995年成为一名注册会计师。她担任董事会副主席，2011年至2020年担任旧金山消防信用合作社审计委员会主席。
- Bridget O'Rourke,has served on the Board since April 2017. Ms. O'Rourke has held a number of executive and leadership positions over more than twenty years, with expertise across different industries. Most recently, Ms.O'Rourke served as Executive Director of the executive search and consulting practice of O'Rourke & Associates, a boutique firm providing services exclusively for the credit union industry, from July 2016 until May 2017. From August 2008 to June 2016, Ms.O'Rourke was Head of Human Resources at Passport Capital, LLC, a global asset management firm. Prior to Passport Capital, LLC, from 1997 to 2007 Ms.O'Rourke served in various positions in the financial services and executive search industries, including as Executive Search Director at O'Rourke Career Connections, Controller at Sigma Partners, a multi-fund venture capital firm, and Vice President for Citibank Global Asset Management's Alternative Investment Strategies group. From July 1991 to December 1996, Ms.O'Rourke held audit and internal audit consulting positions of increasing responsibility at Coopers & Lybrand (now known as PricewaterhouseCoopers). Ms.O'Rourke received a B.A. from the University of California, Santa Barbara and became a Certified Public Accountant in 1995. She served on the Board of Directors as Vice Chair and was Audit Committee Chair of the San Francisco Fire Credit Union from 2011 through 2020.
- Thomas Wilder
-
Thomas Wilder，自2017年1月起在董事会任职，自2025年4月起担任董事会主席。Wilder先生目前担任神经血管公司VS3 Medical，Inc.的首席执行官。2017年8月至2023年9月，Wilder先生担任神经调节公司Neuros Medical，Inc.的总裁兼首席执行官。从2010年2月到2016年7月，Wilder先生担任Sequent Medical，Inc.的首席执行官，该公司致力于开发创新的基于导管的神经血管技术。2006年4月至2009年，Wilder先生担任PhotoThera，Inc.的总裁兼首席执行官，该公司正在为急性缺血性脑卒中患者开发一种独特的疗法。2002年至2006年，他担任MicroTherapeutics，Inc.（MTIX）的总裁兼首席执行官，该公司也专注于神经血管领域。Wilder先生从1991年到2002年在美敦力公司担任越来越重要的职务，最近担任其血管内支架移植部门的副总裁兼总经理。Wilder先生的职业生涯始于普华永道的财务报表审计业务，他曾于1986年至1989年在那里工作。Wilder先生还自2025年7月起担任Grey Matter Neurosciences的董事会成员。他获得了斯坦福大学的学士学位和西北大学家乐氏管理研究生院的工商管理硕士学位。
Thomas Wilder,has served on the Board since January 2017 and as Presiding Director of the Board since April 2025. Mr. Wilder currently serves as the Chief Executive Officer of VS3 Medical, Inc., a neurovascular company. From August 2017 to September 2023, Mr. Wilder served as the President and Chief Executive Officer of Neuros Medical, Inc., a neuro-modulation company. From February 2010 through July 2016, Mr. Wilder served as the Chief Executive Officer of Sequent Medical, Inc., a company dedicated to the development of innovative catheter-based neurovascular technologies. From April 2006 to 2009, Mr. Wilder served as the President and CEO of PhotoThera, Inc., a company that was developing a unique therapy for acute ischemic stroke patients. From 2002 to 2006, he served as the President and CEO of MicroTherapeutics, Inc. (MTIX), a company also focused on the neurovascular space. Mr. Wilder served in positions of increasing responsibility at Medtronic, Inc. from 1991 through 2002, most recently as Vice President and General Manager of its endovascular stent grafts division. Mr. Wilder began his career in the Financial Statement Audit Practice of Price Waterhouse, where he worked from 1986 to 1989. Mr. Wilder has also served on the Board of Directors of Grey Matter Neurosciences since July 2025. He received a B.A. from Stanford University and an M.B.A. from Northwestern University's Kellogg Graduate School of Management. - Thomas Wilder，自2017年1月起在董事会任职，自2025年4月起担任董事会主席。Wilder先生目前担任神经血管公司VS3 Medical，Inc.的首席执行官。2017年8月至2023年9月，Wilder先生担任神经调节公司Neuros Medical，Inc.的总裁兼首席执行官。从2010年2月到2016年7月，Wilder先生担任Sequent Medical，Inc.的首席执行官，该公司致力于开发创新的基于导管的神经血管技术。2006年4月至2009年，Wilder先生担任PhotoThera，Inc.的总裁兼首席执行官，该公司正在为急性缺血性脑卒中患者开发一种独特的疗法。2002年至2006年，他担任MicroTherapeutics，Inc.（MTIX）的总裁兼首席执行官，该公司也专注于神经血管领域。Wilder先生从1991年到2002年在美敦力公司担任越来越重要的职务，最近担任其血管内支架移植部门的副总裁兼总经理。Wilder先生的职业生涯始于普华永道的财务报表审计业务，他曾于1986年至1989年在那里工作。Wilder先生还自2025年7月起担任Grey Matter Neurosciences的董事会成员。他获得了斯坦福大学的学士学位和西北大学家乐氏管理研究生院的工商管理硕士学位。
- Thomas Wilder,has served on the Board since January 2017 and as Presiding Director of the Board since April 2025. Mr. Wilder currently serves as the Chief Executive Officer of VS3 Medical, Inc., a neurovascular company. From August 2017 to September 2023, Mr. Wilder served as the President and Chief Executive Officer of Neuros Medical, Inc., a neuro-modulation company. From February 2010 through July 2016, Mr. Wilder served as the Chief Executive Officer of Sequent Medical, Inc., a company dedicated to the development of innovative catheter-based neurovascular technologies. From April 2006 to 2009, Mr. Wilder served as the President and CEO of PhotoThera, Inc., a company that was developing a unique therapy for acute ischemic stroke patients. From 2002 to 2006, he served as the President and CEO of MicroTherapeutics, Inc. (MTIX), a company also focused on the neurovascular space. Mr. Wilder served in positions of increasing responsibility at Medtronic, Inc. from 1991 through 2002, most recently as Vice President and General Manager of its endovascular stent grafts division. Mr. Wilder began his career in the Financial Statement Audit Practice of Price Waterhouse, where he worked from 1986 to 1989. Mr. Wilder has also served on the Board of Directors of Grey Matter Neurosciences since July 2025. He received a B.A. from Stanford University and an M.B.A. from Northwestern University's Kellogg Graduate School of Management.
- Janet Leeds
-
Janet Leeds，自2019年1月起担任董事会成员。利兹女士在超过35年的时间里，在学术医疗环境中担任过多个领导和咨询职务。目前，Leeds女士担任Fred Hutchinson癌症中心的行政主管。从2005年到2009年，利兹女士担任Fred Hutchinson/华盛顿大学癌症联盟的管理员。从2000年到2005年，Leeds女士担任Fred Hutchinson癌症研究中心的规划主任。从1996年到2000年，利兹女士担任过多个职位，这些职位对西雅图癌症护理联盟的形成和发展起到了重要作用。在此之前，从1987年到1995年，Leeds女士在ECG Management Consultants担任的管理顾问职位责任越来越大，在那里她主要向学术医疗中心提供咨询。利兹女士获得了斯坦福大学的学士学位和华盛顿大学的工商管理硕士学位。
Janet Leeds,has served on the Board since January 2019. Ms. Leeds has held a number of leadership and consulting roles in academic healthcare settings over more than thirty-five years. Currently, Ms. Leeds serves as an Administrative Director at the Fred Hutchinson Cancer Center. From 2005 to 2009, Ms. Leeds served as the Administrator for the Fred Hutchinson/University of Washington Cancer Consortium. From 2000 to 2005, Ms. Leeds served as the Director of Planning at the Fred Hutchinson Cancer Research Center. From 1996 to 2000, Ms. Leeds served in various positions that were instrumental to the formation and development of the Seattle Cancer Care Alliance. Prior to that, from 1987 to 1995, Ms. Leeds held management consultant positions of increasing responsibility at ECG Management Consultants, where she primarily consulted with academic medical centers. Ms. Leeds received a B.A. from Stanford University and an M.B.A. from the University of Washington. - Janet Leeds，自2019年1月起担任董事会成员。利兹女士在超过35年的时间里，在学术医疗环境中担任过多个领导和咨询职务。目前，Leeds女士担任Fred Hutchinson癌症中心的行政主管。从2005年到2009年，利兹女士担任Fred Hutchinson/华盛顿大学癌症联盟的管理员。从2000年到2005年，Leeds女士担任Fred Hutchinson癌症研究中心的规划主任。从1996年到2000年，利兹女士担任过多个职位，这些职位对西雅图癌症护理联盟的形成和发展起到了重要作用。在此之前，从1987年到1995年，Leeds女士在ECG Management Consultants担任的管理顾问职位责任越来越大，在那里她主要向学术医疗中心提供咨询。利兹女士获得了斯坦福大学的学士学位和华盛顿大学的工商管理硕士学位。
- Janet Leeds,has served on the Board since January 2019. Ms. Leeds has held a number of leadership and consulting roles in academic healthcare settings over more than thirty-five years. Currently, Ms. Leeds serves as an Administrative Director at the Fred Hutchinson Cancer Center. From 2005 to 2009, Ms. Leeds served as the Administrator for the Fred Hutchinson/University of Washington Cancer Consortium. From 2000 to 2005, Ms. Leeds served as the Director of Planning at the Fred Hutchinson Cancer Research Center. From 1996 to 2000, Ms. Leeds served in various positions that were instrumental to the formation and development of the Seattle Cancer Care Alliance. Prior to that, from 1987 to 1995, Ms. Leeds held management consultant positions of increasing responsibility at ECG Management Consultants, where she primarily consulted with academic medical centers. Ms. Leeds received a B.A. from Stanford University and an M.B.A. from the University of Washington.
- Surbhi Sarna
-
Surbhi Sarna，自2019年7月起担任董事会成员。Sarna女士是Collate Software，Inc.的首席执行官和创始人，该公司专注于使用人工智能为生命科学公司创建和简化文档。从2020年9月至2025年1月，Sarna女士担任Y Combinator的普通合伙人。2011年，Sarna女士创立了nVision Medical Corp（nVision），这是一家开发开创性技术以实现卵巢癌早期检测的医疗保健公司，目的是满足未满足的临床需求。她领导这家公司从成立之初就经历了产品开发、资金和初步临床试验的最初阶段。2018年4月，NVision被波士顿科学收购，Sarna女士在波士顿科学领导NVision开发的技术商业化工作至2020年7月。在创立nVision之前，Sarna女士在医疗保健领域担任过多种职务，包括在BioCardia和Abbott Vascular任职。Sarna女士还于2021年7月至2023年7月在Biora Therapeutics, Inc.（前身为Progenity, Inc.）的董事会任职。Sarna女士获得了加州大学伯克利分校的学士学位。
Surbhi Sarna,has served on the Board since July 2019. Ms. Sarna is CEO and Founder of Collate Software, Inc., a company focused on using artificial intelligence to create and streamline documentation for life science companies. From September 2020 to January 2025, Ms. Sarna served as a General Partner at Y Combinator. In 2011, Ms. Sarna founded nVision Medical Corp (nVision), a healthcare company developing pioneering technology to enable early detection of ovarian cancer, with the intention of fulfilling an unmet clinical need. She led the company from its inception and through its earliest days of product development, funding and initial clinical trials. In April 2018, nVision was acquired by Boston Scientific, and Ms. Sarna led the efforts to commercialize the technology developed by nVision at Boston Scientific through July 2020. Prior to her founding of nVision, Ms. Sarna held a variety of roles in healthcare, including roles at BioCardia and Abbott Vascular. Ms. Sarna also served on the Board of Directors of Biora Therapeutics, Inc. (formerly Progenity, Inc.) from July 2021 to July 2023. Ms. Sarna received a BA from the University of California, Berkeley. - Surbhi Sarna，自2019年7月起担任董事会成员。Sarna女士是Collate Software，Inc.的首席执行官和创始人，该公司专注于使用人工智能为生命科学公司创建和简化文档。从2020年9月至2025年1月，Sarna女士担任Y Combinator的普通合伙人。2011年，Sarna女士创立了nVision Medical Corp（nVision），这是一家开发开创性技术以实现卵巢癌早期检测的医疗保健公司，目的是满足未满足的临床需求。她领导这家公司从成立之初就经历了产品开发、资金和初步临床试验的最初阶段。2018年4月，NVision被波士顿科学收购，Sarna女士在波士顿科学领导NVision开发的技术商业化工作至2020年7月。在创立nVision之前，Sarna女士在医疗保健领域担任过多种职务，包括在BioCardia和Abbott Vascular任职。Sarna女士还于2021年7月至2023年7月在Biora Therapeutics, Inc.（前身为Progenity, Inc.）的董事会任职。Sarna女士获得了加州大学伯克利分校的学士学位。
- Surbhi Sarna,has served on the Board since July 2019. Ms. Sarna is CEO and Founder of Collate Software, Inc., a company focused on using artificial intelligence to create and streamline documentation for life science companies. From September 2020 to January 2025, Ms. Sarna served as a General Partner at Y Combinator. In 2011, Ms. Sarna founded nVision Medical Corp (nVision), a healthcare company developing pioneering technology to enable early detection of ovarian cancer, with the intention of fulfilling an unmet clinical need. She led the company from its inception and through its earliest days of product development, funding and initial clinical trials. In April 2018, nVision was acquired by Boston Scientific, and Ms. Sarna led the efforts to commercialize the technology developed by nVision at Boston Scientific through July 2020. Prior to her founding of nVision, Ms. Sarna held a variety of roles in healthcare, including roles at BioCardia and Abbott Vascular. Ms. Sarna also served on the Board of Directors of Biora Therapeutics, Inc. (formerly Progenity, Inc.) from July 2021 to July 2023. Ms. Sarna received a BA from the University of California, Berkeley.
高管简历
中英对照 | 中文 | 英文- Adam Elsesser
Adam Elsesser联合创立了Penumbra并自公司于2004年成立起担任首席执行官和董事会成员，2015年1月成为公司的董事长和总裁。在Penumbra之前，Elsesser先生领导了SMART Therapeutics股份有限公司（SMART Therapeutics, Inc.，一家医疗设备公司，专注于神经介入治疗装置），担任首席执行官（2000-2002年），并且，后来被Boston Scientific 公司（Boston Scientific Corporation）收购，2002-2005年担任Boston Scientific 公司（Boston Scientific Corporation）的智能疗法的总裁。在他在医疗设备行业工作之前，Elsesser先生是律师事务所Shartsis Friese有限责任合伙公司（Shartsis Friese, LLP）的合伙人。他拥有斯坦福大学（Stanford University ）学士学位和黑斯廷斯法律学院（Hastings College of the Law）博士学位。
Adam Elsesser,co-founded Penumbra and has served as Chief Executive Officer and a member of the Board since inception in June 2004, as Chairman of the Board since January 2015, and as President from January 2015 until August 2019 and again from May 2020 until September 2025. Prior to Penumbra, Mr. Elsesser led SMART Therapeutics, Inc. (SMART Therapeutics), a medical device company focused on devices for neuro-intervention, as its Chief Executive Officer from 2000 to 2002 and, after its acquisition by Boston Scientific Corporation, as President of SMART Therapeutics within Boston Scientific Corporation from 2002 to 2005. Before his work in the medical device industry, Mr. Elsesser was a partner in the law firm of Shartsis Friese LLP. Mr. Elsesser received a B.A. from Stanford University and a J.D. from UC Law San Francisco, formerly Hastings College of the Law.- Adam Elsesser联合创立了Penumbra并自公司于2004年成立起担任首席执行官和董事会成员，2015年1月成为公司的董事长和总裁。在Penumbra之前，Elsesser先生领导了SMART Therapeutics股份有限公司（SMART Therapeutics, Inc.，一家医疗设备公司，专注于神经介入治疗装置），担任首席执行官（2000-2002年），并且，后来被Boston Scientific 公司（Boston Scientific Corporation）收购，2002-2005年担任Boston Scientific 公司（Boston Scientific Corporation）的智能疗法的总裁。在他在医疗设备行业工作之前，Elsesser先生是律师事务所Shartsis Friese有限责任合伙公司（Shartsis Friese, LLP）的合伙人。他拥有斯坦福大学（Stanford University ）学士学位和黑斯廷斯法律学院（Hastings College of the Law）博士学位。
- Adam Elsesser,co-founded Penumbra and has served as Chief Executive Officer and a member of the Board since inception in June 2004, as Chairman of the Board since January 2015, and as President from January 2015 until August 2019 and again from May 2020 until September 2025. Prior to Penumbra, Mr. Elsesser led SMART Therapeutics, Inc. (SMART Therapeutics), a medical device company focused on devices for neuro-intervention, as its Chief Executive Officer from 2000 to 2002 and, after its acquisition by Boston Scientific Corporation, as President of SMART Therapeutics within Boston Scientific Corporation from 2002 to 2005. Before his work in the medical device industry, Mr. Elsesser was a partner in the law firm of Shartsis Friese LLP. Mr. Elsesser received a B.A. from Stanford University and a J.D. from UC Law San Francisco, formerly Hastings College of the Law.
- Johanna Roberts
约翰娜·罗伯茨，2014年加入Penumbra。她从2015年7月起担任副总裁兼副总法律顾问，直到2018年9月晋升为执行副总裁、总法律顾问和秘书。在加入Penumbra之前，Roberts女士曾在多家律师事务所工作了十五年，其中包括旧金山的Morrison & Foerster LLP。罗伯茨女士获得了达特茅斯学院的学士学位和哈佛法学院的法学博士学位。
Johanna Roberts,joined Penumbra in 2014. She served as Vice President and Deputy General Counsel from July 2015 until her promotion to Executive Vice President, General Counsel and Secretary in September 2018. Prior to joining Penumbra, Ms. Roberts had fifteen years' experience working for several law firms, including Morrison & Foerster LLP in San Francisco. Ms. Roberts received a B.A. from Dartmouth College and J.D. from Harvard Law School.- 约翰娜·罗伯茨，2014年加入Penumbra。她从2015年7月起担任副总裁兼副总法律顾问，直到2018年9月晋升为执行副总裁、总法律顾问和秘书。在加入Penumbra之前，Roberts女士曾在多家律师事务所工作了十五年，其中包括旧金山的Morrison & Foerster LLP。罗伯茨女士获得了达特茅斯学院的学士学位和哈佛法学院的法学博士学位。
- Johanna Roberts,joined Penumbra in 2014. She served as Vice President and Deputy General Counsel from July 2015 until her promotion to Executive Vice President, General Counsel and Secretary in September 2018. Prior to joining Penumbra, Ms. Roberts had fifteen years' experience working for several law firms, including Morrison & Foerster LLP in San Francisco. Ms. Roberts received a B.A. from Dartmouth College and J.D. from Harvard Law School.
- Lambert Shiu
Lambert Shiu，2015年加入Penumbra，担任财务总监，后担任财务和会计副总裁，至2019年12月晋升为首席会计官。在加入Penumbra之前，Shiu先生曾在普华永道会计师事务所（PWC）工作超过13年。在普华永道任职期间，他曾在多个团队工作，每个角色的责任和管理水平都在提高，并在其国家办公室工作了两年。Shiu先生是加利福尼亚州的一名注册会计师，并获得了加州大学戴维斯分校的学士学位。
Lambert Shiu,joined Penumbra in 2015, serving as Director of Finance, then as Vice President, Finance and Accounting until his promotion to Chief Accounting Officer in December 2019. Prior to joining Penumbra, Mr. Shiu worked for PricewaterhouseCoopers LLP (PwC), an accounting firm, for over 13 years. He worked on a variety of teams during his tenure at PwC, each role increasing in levels of responsibility and management and spent two years in their National Office. Mr. Shiu is a Certified Public Accountant in California and received a B.A. from the University of California, Davis.- Lambert Shiu，2015年加入Penumbra，担任财务总监，后担任财务和会计副总裁，至2019年12月晋升为首席会计官。在加入Penumbra之前，Shiu先生曾在普华永道会计师事务所（PWC）工作超过13年。在普华永道任职期间，他曾在多个团队工作，每个角色的责任和管理水平都在提高，并在其国家办公室工作了两年。Shiu先生是加利福尼亚州的一名注册会计师，并获得了加州大学戴维斯分校的学士学位。
- Lambert Shiu,joined Penumbra in 2015, serving as Director of Finance, then as Vice President, Finance and Accounting until his promotion to Chief Accounting Officer in December 2019. Prior to joining Penumbra, Mr. Shiu worked for PricewaterhouseCoopers LLP (PwC), an accounting firm, for over 13 years. He worked on a variety of teams during his tenure at PwC, each role increasing in levels of responsibility and management and spent two years in their National Office. Mr. Shiu is a Certified Public Accountant in California and received a B.A. from the University of California, Davis.
- Maggie Yuen
Maggie Yuen，于2019年12月加入Penumbra，担任首席财务官。在加入Penumbra之前，Yuen女士花了20多年时间推动制造、医疗设备和生命科学行业的可扩展金融组织、流程和基础设施。她曾于2016年至2019年在赛默飞世尔，Inc.（纽约证券交易所代码：TMO）（赛默飞世尔）内担任基因科学部门的财务副总裁，该公司的业务专注于仪器平台、基于云的软件、内容和服务。在她的角色中，Yuen女士指导了财务运营、战略规划和业务发展活动，以及其他多项执行职能。在加入赛默飞世尔之前，Yuen女士曾在Mirion Technologies担任责任越来越大的领导职务（2012年至2016年），并在波士顿科学（NYSE：BSX）（2007年至2010年）、Glu移动（纳斯达克：GLUU）（2004年至2007年）和强生（NYSE：JNJ）（2001年至2004年）担任高级财务职务。Yuen女士还自2021年6月起担任AtriCure，Inc.（纳斯达克：ATRC）的董事会成员。Yuen女士获得了Weatherhead管理学院的MAC和MBA学位，以及凯斯西储大学的学士学位。
Maggie Yuen,joined Penumbra as Chief Financial Officer in December 2019. Prior to joining Penumbra, Ms. Yuen spent more than 20 years driving scalable finance organizations, processes and infrastructure in the Manufacturing, Medical Devices, and Life Science industries. She served as Vice President of Finance of the Genetic Science Division within Thermo Fisher Scientific, Inc. (NYSE: TMO) (Thermo Fisher), a business focused on instrument platforms, cloud-based software, content and services, from 2016 to 2019. In her role, Ms. Yuen directed finance operations, strategic planning and business development activities, among a number of other executive functions. Prior to Thermo Fisher, Ms. Yuen held leadership positions with increasing responsibility at Mirion Technologies (from 2012 to 2016), and senior finance roles at Boston Scientific (NYSE: BSX) (from 2007 to 2010), Glu Mobile (Nasdaq: GLUU) (from 2004 to 2007), and Johnson & Johnson (NYSE: JNJ) (from 2001 to 2004). Ms. Yuen has also served on the Board of Directors of AtriCure, Inc. (Nasdaq: ATRC) since June 2021. Ms. Yuen received an MAcc and M.B.A. from the Weatherhead School of Management and a B.S. from Case Western Reserve University.- Maggie Yuen，于2019年12月加入Penumbra，担任首席财务官。在加入Penumbra之前，Yuen女士花了20多年时间推动制造、医疗设备和生命科学行业的可扩展金融组织、流程和基础设施。她曾于2016年至2019年在赛默飞世尔，Inc.（纽约证券交易所代码：TMO）（赛默飞世尔）内担任基因科学部门的财务副总裁，该公司的业务专注于仪器平台、基于云的软件、内容和服务。在她的角色中，Yuen女士指导了财务运营、战略规划和业务发展活动，以及其他多项执行职能。在加入赛默飞世尔之前，Yuen女士曾在Mirion Technologies担任责任越来越大的领导职务（2012年至2016年），并在波士顿科学（NYSE：BSX）（2007年至2010年）、Glu移动（纳斯达克：GLUU）（2004年至2007年）和强生（NYSE：JNJ）（2001年至2004年）担任高级财务职务。Yuen女士还自2021年6月起担任AtriCure，Inc.（纳斯达克：ATRC）的董事会成员。Yuen女士获得了Weatherhead管理学院的MAC和MBA学位，以及凯斯西储大学的学士学位。
- Maggie Yuen,joined Penumbra as Chief Financial Officer in December 2019. Prior to joining Penumbra, Ms. Yuen spent more than 20 years driving scalable finance organizations, processes and infrastructure in the Manufacturing, Medical Devices, and Life Science industries. She served as Vice President of Finance of the Genetic Science Division within Thermo Fisher Scientific, Inc. (NYSE: TMO) (Thermo Fisher), a business focused on instrument platforms, cloud-based software, content and services, from 2016 to 2019. In her role, Ms. Yuen directed finance operations, strategic planning and business development activities, among a number of other executive functions. Prior to Thermo Fisher, Ms. Yuen held leadership positions with increasing responsibility at Mirion Technologies (from 2012 to 2016), and senior finance roles at Boston Scientific (NYSE: BSX) (from 2007 to 2010), Glu Mobile (Nasdaq: GLUU) (from 2004 to 2007), and Johnson & Johnson (NYSE: JNJ) (from 2001 to 2004). Ms. Yuen has also served on the Board of Directors of AtriCure, Inc. (Nasdaq: ATRC) since June 2021. Ms. Yuen received an MAcc and M.B.A. from the Weatherhead School of Management and a B.S. from Case Western Reserve University.
- Shruthi Narayan
Shruthi Narayan，2013年加入Penumbra，从Stroke特许经营起步担任产品经理，随后转型帮助建立外周血管部门，并在全球范围内将Penumbra的血管栓塞和取栓产品组合商业化。2023年9月，Narayan女士晋升为Interventional执行副总裁兼总经理，并自2025年1月起担任Interventional总裁，直至2025年9月被任命为Penumbra总裁。在加入Penumbra之前，Narayan女士曾在美敦力，Inc.从事工程、法规事务工作，之后任职于心血管销售组织。Narayan女士获得了印度安娜大学的电气工程学士学位和南加州大学的生物医学工程硕士学位，重点是医疗设备商业化。
Shruthi Narayan,joined Penumbra in 2013, serving as a product manager starting off on the Stroke franchise, then transitioning to help build the Peripheral Vascular division and commercialize Penumbra's vascular portfolio of embolization and thrombectomy products globally. In September 2023, Ms. Narayan was promoted to EVP and General Manager, Interventional, and also served as President, Interventional from January 2025 until her appointment as President of Penumbra in September 2025. Prior to joining Penumbra, Ms. Narayan worked for Medtronic, Inc. in engineering, regulatory affairs and then in the cardiovascular sales organization. Ms. Narayan received a B.S. in Electrical Engineering from Anna University, India and a M.S. in Biomedical Engineering from University of Southern California, with a focus on Medical Device Commercialization.- Shruthi Narayan，2013年加入Penumbra，从Stroke特许经营起步担任产品经理，随后转型帮助建立外周血管部门，并在全球范围内将Penumbra的血管栓塞和取栓产品组合商业化。2023年9月，Narayan女士晋升为Interventional执行副总裁兼总经理，并自2025年1月起担任Interventional总裁，直至2025年9月被任命为Penumbra总裁。在加入Penumbra之前，Narayan女士曾在美敦力，Inc.从事工程、法规事务工作，之后任职于心血管销售组织。Narayan女士获得了印度安娜大学的电气工程学士学位和南加州大学的生物医学工程硕士学位，重点是医疗设备商业化。
- Shruthi Narayan,joined Penumbra in 2013, serving as a product manager starting off on the Stroke franchise, then transitioning to help build the Peripheral Vascular division and commercialize Penumbra's vascular portfolio of embolization and thrombectomy products globally. In September 2023, Ms. Narayan was promoted to EVP and General Manager, Interventional, and also served as President, Interventional from January 2025 until her appointment as President of Penumbra in September 2025. Prior to joining Penumbra, Ms. Narayan worked for Medtronic, Inc. in engineering, regulatory affairs and then in the cardiovascular sales organization. Ms. Narayan received a B.S. in Electrical Engineering from Anna University, India and a M.S. in Biomedical Engineering from University of Southern California, with a focus on Medical Device Commercialization.